Annual Gala Celebrates Advances in Prostate Cancer Research and Treatment at Mount Sinai

Frorm left: James Tisch, Co-Chairman of the Boards of Trustees of the Mount Sinai Health System, Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and Ash Tewari, MBBS, MCh.

The Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai hosted its annual Prostate Cancer Research Gala and exceeded its goal of raising more than $1 million for the Center of Excellence for Prostate Cancer within the Department of Urology. Its mission is to eliminate prostate cancer through programs that support innovative research, patient care, prevention, and education for students, trainees, professionals, and the public.

“We are fortunate that at Mount Sinai the best minds across specialties like immunology, pathology, medical oncology, radiology, and others collaborate with the common goal of making prostate cancer insignificant while improving the quality of life for our patients,” said Ash Tewari, MBBS, MCh, Chair of the Department of Urology at the Mount Sinai Health System and the Kyung Hyun Kim, MD Professor of Urology at Icahn Mount Sinai, who spearheaded the gala and directs the Center of Excellence.

Goutam Chakraborty, PhD, left, and Dr. Charney

More than 200 people attended the event, which was held Wednesday, April 10, at the Rainbow Room in Rockefeller Center. Actor and singer Peter Gallagher served as the emcee for the evening.

At the event, the second annual Steven Southwick, MD Memorial Award was presented to Goutam Chakraborty, PhD, Assistant Professor, Urology, and Oncological Sciences and a member of The Tisch Cancer Institute at Mount Sinai. Named after renowned researcher and scientist Steven M. Southwick—a leading expert in psychological trauma and human resilience, who passed away in 2022 after a lengthy battle with prostate cancer—this award recognizes outstanding achievements in prostate cancer research.

Dr. Chakraborty was honored for his focus on lethal metastatic prostate cancer, which has no available treatments. He and his team made the groundbreaking discovery that the BRCA2 gene—most commonly known for its link to breast cancer—also has a connection to prostate cancer. Dr. Chakraborty is now looking at how mutations of genes like BRCA2 change cells from benign to metastatic disease, potentially leading to important new therapies.

“Research is like climbing a mountain, like climbing Everest, but we have not reached the top of Everest yet,” said Dr. Chakraborty in a video shown at the event. “Every day is a different challenge.”

Dr. Tewari, left, and John A. Levin

The gala also honored John A. Levin, who was recognized for his extraordinary commitment to the Prostate Cancer Program and longtime leadership on the Mount Sinai Board of Trustees. Dr. Tewari praised Mr. Levin’s unwavering support of the Mount Sinai Health System’s efforts to redefine cancer care, including his involvement with the International Prostate Cancer and Urology Symposium held at Mount Sinai, which draws the world’s top experts together to explore the latest advancements and challenges in urological cancer.

“His philanthropy has made an immense impact, not just on our prostate cancer program, but on a global understanding of prostate cancer, and to Mount Sinai itself, guiding and supporting research in different subspecialties,” said Dr. Tewari in a video.

In accepting the award, Mr. Levin noted that he’s proud to be part of Mount Sinai’s extraordinary service to New York City and beyond.

“We treat an enormous number of people. It is also an education arm and a research institution which creates new drugs, creates new devices,” he said in a video. “It’s really being part of a community and I want to help that community in whatever limited capacity I can.”

Advancing Heath Equity With Data: Collaborating With Stakeholders at Mount Sinai Queens

Jill Goldstein, MA, MS, RN

At Mount Sinai, a key pillar in advancing health equity focuses on the collection and use of self-reported patient demographic data to identify gaps in care. The Health Equity Data Assessment (HEDA) team is engaging key stakeholders across the Health System and collaborating to address variances.

A highlight of these efforts is the Mount Sinai Queens Nurses Against Racism (NAR) system council, which endeavored to evaluate incidences of hospital-acquired pressure injuries (HAPI) using an equity lens.

A pressure injury is a localized injury to the skin and/or underlying tissue, resulting from compression between a bony prominence and an external surface for a prolonged time. Monitoring HAPI specifically focuses on the occurrence of these injuries during an inpatient hospital stay.

According to Jill Goldstein, MA, MS, RN, Deputy Chief Nursing Officer, Vice President of Nursing at Mount Sinai Queens, and NAR sponsor, their collaboration with HEDA began in January 2023, combining subject matter expertise and data modeling to evaluate differences in HAPI rates across patient populations. She  noted that the interdisciplinary team explored the impact of race, gender, age, language, payor, length of stay, clinical service, and other factors on the incidences of hospital-acquired pressure injuries.

Further, the data showed that in terms of race, there were no meaningful differences observed between white, Black, or Hispanic patients in any model.

Notably, the most actionable finding was the elevated risk for patients who prefer to speak a language other than English or Spanish. In these patients, 40 percent were more likely to have documented HAPI when compared to English-speaking patients.

With the data the HEDA team helped to collect and interpret, the system-wide nursing team will seek interventions to eliminate this disparity. This interdisciplinary approach serves as a model to incorporate an equity lens into other quality work, according to Ms. Goldstein.

Purple Day: Raising Awareness, Ending Stigma of Epilepsy

Every year on March 26, people and organizations around the world band together in solidarity for Purple Day. They wear purple and host events to raise awareness about epilepsy, with the goal of ending its stigma. For Purple Day this year, we got together experts from the Mount Sinai Health System to explain what epilepsy is and answer other top questions people might have.

Is epilepsy contagious?
“You cannot spread epilepsy from one person to the other,” says pediatric neurologist Natasha Acosta Diaz, MD, Assistant Professor of Neurology at the Icahn School of Medicine at Mount Sinai.

Epilepsy is not an infection. It is a neurological condition characterized by seizures caused by abnormal brain electrical activity, says Dr. Acosta Diaz.

Is epilepsy electroencephalogram (EEG) testing painful?
In a standard EEG test, electrodes—small metal discs—are attached to the scalp with the help of a glue. The EEG test is not painful, says Anuradha Singh, MD, Director of the Epilepsy Monitoring Unit, and Professor of Neurology at Icahn Mount Sinai.

EEG tests study brain rhythms to look for any sign of irritability.  A standard EEG test records these brain rhythms for 20 minutes to an hour, says Dr. Singh. “Sometimes you get a little glue left on your scalp but it’s not painful at all,” she adds.

Is epilepsy surgery dangerous?
“The myths about the danger of epilepsy surgery come from the past, from about the last 100 years or so,” says neurosurgeon Fedor Panov, MD, Director of the Adult Epilepsy Surgery Program and Associate Professor of Neurosurgery at Icahn Mount Sinai. “What you currently find on the internet (about the dangers) unfortunately is not appropriate and it just perpetuates this myth that epilepsy surgery is dangerous,” he notes.

Epilepsy surgery has its risks and benefits. “Most certainly, the benefits outweigh the risks,” says Dr. Panov. As the epilepsy care team might phrase it to patients, the risk of going through a year with epileptic seizures far outweighs the risk of a surgical intervention to cure the epilepsy, he says.

Can epilepsy seizures be triggered by flashing lights?
There is a type of epilepsy that can be triggered by flashing lights, called photosensitive epilepsy. “However, this is very rare,” says Dr. Acosta Diaz.

When testing a patient for epilepsy, flashing lights are used to see if they provoke a seizure, and if so, appropriate recommendations for care can be given, she adds.

Can people with epilepsy drive a car?
“You can drive a car if you’re seizure-free,” says Dr. Singh. However, different states can have different rules and regulations. People with epilepsy will have to check with their state’s Department of Motor Vehicles, she notes.

What are some epilepsy surgical options?

Vagal nerve stimulator
Involves placing a small wire around a nerve in the neck to decrease seizure activity. The wire is attached to a small battery inserted under the skin of the chest.

Stereotactic laser ablation
Uses lasers to remove a part of the temporal lobe of the brain to help control seizures. The procedure is guided by magnetic resonance imaging (MRI), allowing for very precise cuts and removal.

Staged craniotomy
A two-stage surgery that involves removal of part of the skull to expose the brain, followed by removal of the brain tissue that is causing the seizures. Removing the damaged part of the brain does not cause deficits, as other parts of the brain adapt and pick up function. The procedure improves the overall brain network because it allows the healthy areas to work without constant electrical interference from the seizure “hot spot.”

Responsive neurostimulation
A device is implanted that automatically records and detects electrographic seizures, then rapidly delivers electrical stimulation to suppress seizure activity. It is the first device that the U.S. Food and Drug Administration has approved for use in the brain to listen, learn, and respond to seizures.

Can people with epilepsy have a job?
“Absolutely,” says Dr. Panov. “It’s a myth to say you cannot work if you have seizures.” Epilepsy care teams are available to help patients be a part of their community, including having and holding jobs. The Americans with Disabilities Act prohibits discrimination against people with disabilities in several areas, including employment.

While it is not mandatory that people with epilepsy disclose their condition to employers or coworkers, it is recommended that someone at the workplace is aware, says Dr. Acosta Diaz. “Just in case you have a seizure, somebody can be with you or help you,” she says.

Can people with epilepsy have children?
People with epilepsy can have happy, healthy children, says Dr. Singh. Women with epilepsy should work with their OB/GYN and epileptologist to ensure they’re on the safest drugs for the pregnancy, says Dr. Singh.

Can people with epilepsy stop taking medications when seizures stop?
The goal of any Comprehensive Epilepsy Center is to get patients seizure-free, and ultimately off the medications, says Dr. Panov: “The idea is that you will come off your meds once the seizures stop.”

It is important, however, that patients do not stop taking medications without discussing with their specialists, says Dr. Singh. A lot of factors go into the consideration of stopping medications, including EEG results and MRI scans, so that process should be done in consultation with an epileptologist.

Can people with epilepsy swallow their tongue?
“No way, there’s no way that you’re going to swallow your tongue,” says Dr. Acosta Diaz. During a seizure, the tongue can go to the side of the mouth and people can accidentally bite their tongue. To assist someone with a seizure, be calm and lay the person on the side, and definitely do not put anything in the mouth, such as a spoon, she says.

Does a ketogenic diet help people with epilepsy?
It does, in certain cases, says Dr. Singh. A ketogenic diet is a high-fat, adequate-protein, and low-carbohydrate diet. It is more often used in pediatric epilepsy, especially for children in whom medications do not work well, says Dr. Acosta Diaz.

Ketosis, a state where the body derives its sources of energy from fat rather than glucose, is known to have anticonvulsant properties. However, it’s not easy for a person to enter into ketosis. That is why an epilepsy care team involves overseeing a patient’s metabolism and nutrition as well, notes Dr. Acosta Diaz. “It’s not something you can try by yourself at home. It’s not just doing a keto diet to lose weight,” she says.

Caring for people with epilepsy is a team effort. At the Mount Sinai Epilepsy Center, staff members across all levels of care work together to provide exceptional care. Here’s the Center at a glance:

100+ team members

• Adult epileptologists  • Pediatric epileptologists  • Neurosurgeons  • Neuropsychiatrists  • Neuroradiologists  • Nurse practitioners  • Neurosurgery  • NPs and PAs  • Researchers  • Registered nurses  • Social workers  • Dietitians  • Recreational therapists  • EEG technicians  • Administrative staff

 

 

Designated as a Level 4 medical facility by the National Association of Epilepsy Centers (NAEC), which is the highest recognition of care and expertise for people with epilepsy

Three inpatient Level 4 epilepsy centers at The Mount Sinai Hospital, Mount Sinai Kravis Children’s Hospital, and Mount Sinai West, and six outpatient locations in New York City and Long Island.

ABRET-certified labs

Five Mount Sinai sites have received American Board of Registration of Electroencephalographic and Evoked Potential Technologists (ABRET) Lab accreditation for achieving highest levels of quality and competence performing neurodiagnostic tests.

In 2023

The Mount Sinai Health System performed more than 13,000 electroencephalograms and completed 100 surgeries to reduce or eliminate seizures for adult and pediatric patients.

In addition to treating patients with epilepsy, the Mount Sinai Health System and Icahn Mount Sinai conduct research to push the frontiers of understanding the neurological conditions and what is possible with treatment. Here are some examples of what Mount Sinai is doing to further science in epilepsy.

Clinical trial: Epilepsy associated with Lennox-Gastaut syndrome

Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy, with seizures beginning in early childhood. To treat seizures that have not been well controlled through conventional medication, researchers are using novel responsive neurostimulation (RNS) strategies. This is the first clinical trial using RNS for LGS.

The trial is supported by a five-year grant from the National Institutes of Health, and conducted in collaboration with five other centers in the United States.

Click here for more info.

Clinical trial: Efficacy of subanesthetic doses of IV ketamine for treatment-resistant epilepsy

Ketamine is an anesthetic that provides pain relief, and came into clinical use in the 1960s. In a hospital setting, ketamine is used intravenously at anesthetic doses to treat unrelenting seizures known as status epilepticus in comatose patients. Mount Sinai researchers are exploring using ketamine at subanesthetic doses in an outpatient setting for patients who have treatment-resistant epilepsy. With subanesthestic dose-ketamine recently approved by the FDA for treatment-resistant depression, researchers are optimistic about its safety, and are hopeful that this will provide relief for patients with hard-to-treat epilepsy as well.

Click here for more info.

Clinical trial: Phase 3 trial for a once-daily, oral treatment for those living with focal seizures (XTOLE2)

Focal seizures are when brain cells on one side of the brain malfunction, causing symptoms, and are considered the most common type—making up more than half of all seizures. Symptoms could include one or more of the following: motor, sensory, autonomic, or cognitive. While treatment can stop or reduce the frequency of the seizures, for some patients, current treatment options may be insufficient. Mount Sinai is participating in a Phase 3 study with Xenon Pharmaceuticals to explore the use of XEN1101, a potassium channel opener, along with the patient’s existing medication, for focal seizures. Clinical data from previous trials have shown up to around 50 percent reduction in focal seizures among participants who have received the drug.

Click here for more info.

Clinical trial: Phase 3 trial for Staccato® Alprazolam in participants 12 years and older with stereotypical prolonged seizures

Benzodiazepines are more commonly known for treating anxiety or panic disorders, but they can also be used to terminate most seizures in an inpatient setting. Approved therapies include a rectally-administered gel and intranasal formulations. However, there are no approved treatments for rapidly terminating an ongoing seizure in an outpatient setting. Mount Sinai is participating in a Phase 3 trial with pharmaceutical company UCB to study the effectiveness and safety of Staccato® Alprazolam, a breath-triggered device that delivers the benzodiazepine deep into the lung for rapid absorption and systemic exposure, with the goal of achieving rapid epileptic seizure termination (REST). In a previous clinical trial, in an inpatient setting, nearly 66 percent of participants who received the drug responded to the treatment, compared to 43 percent of participants who received a placebo. For participants who responded to the intervention, the Staccato® Alprazolam group saw seizure cessation in a median time of 30 seconds, compared to 60 seconds for those who had received a placebo. The Phase 3 trial tests the treatment in an outpatient setting.

Click here for more info.

Clinical trial: Electrographic seizure pattern modulation biomarkers in responsive neurostimulation for epilepsy

Although the therapeutic benefit of RNS is well established, predicting how well and when a patient might respond to the device is difficult. It may take several months for a patient to report a reliable change in seizure status, during which time the programming clinician has no objective guidance regarding whether or not to adjust settings. RNS devices can provide EEG recordings, offering an insight to seizure patterns, but there is little knowledge about how to use these recordings in individual patients. Thus, a critical need exists to develop methods for using a patient’s own data to predict when seizure reduction should be expected or to confirm objectively the presence and maintenance of a clinical response.

Icahn Mount Sinai researchers are working with Massachusetts General Hospital to apply machine learning, neurostatistics, and data science to improve the effectiveness of RNS, especially for children and adults who are not considered suitable surgical candidates.

Click here for more info.

Laboratory for Human Neurophysiology

The Laboratory for Human Neurophysiology seeks to understand how human cognition arises from the interaction of multiple brain areas and neurotransmitter systems, particularly in decision-making behavior. These research efforts involve studying prefrontal cortical and subcortical areas directly in the human brain by conducting intracranial electrophysiology recordings in patients undergoing neurosurgical treatment.

Ongoing research projects in the laboratory include investigating the neural basis of human decision-making under uncertainty using distributed intracranial EEG recordings in epilepsy patients, decoding overt subject behavior from preceding, distributed brain activity in reward-related brain regions, and studying reward and mood processing across multiple brain areas in epilepsy patients with and without comorbid depression. The lab is led by Ignacio Saez, PhD, Associate Professor of Neuroscience, Neurosurgery, and Neurology at Icahn Mount Sinai.

Click here to read more about the lab.

Nursing Research Day Highlights the Integral Role Nursing Plays in Advancing Knowledge and Practice

Nurses play an integral role in ensuring successful transitions across settings of care, stages of health, and seasons of life. Their essential contributions extend far beyond direct patient care, with nurse researchers and policy experts leading critical advances in knowledge and practice.

Recently, this research has helped ensure the inclusion of a family caregiver’s name in the medical record of every hospital inpatient upon admission, highlighted the contributors of burnout associated with working in a stressful environment, and produced many other findings and innovations that have translated into better care for patients.

These important contributions to research were highlighted during the Mount Sinai Health System’s Nursing Research Day, organized by the Center for Nursing Research and Innovation (CNRI) at Mount Sinai. Hundreds of nurses participated in the program, which featured nationally renowned experts in research and policy, and 30 poster presentations representing the work of 127 Mount Sinai nurses and colleagues across the greater New York region.

The full-day symposium was held at the Icahn School of Medicine at Mount Sinai and streamed throughout the Health System on Friday, November 10, 2023. The theme was “Crossing the Divide: The Role of Nursing in Navigating Transitions of Care.”

“Thanks to our wonderful planning committee made up of colleagues from across the Health System, Nursing Research Day highlighted research that is shaping nursing practice and policy across the United States at the intersection of community resources and support,” says Bevin Cohen, PhD, MPH, MS, RN, Associate Professor of Geriatric and Palliative Medicine at Icahn Mount Sinai and Director of the CNRI. “It was especially inspiring to see research conducted by our own nursing staff colleagues, who are dedicated to advancing patient care and making a difference in the lives of patients and their families.”

Attendees were welcomed by leaders from across the Health System, including Beth Oliver, DNP, RN, FAAN, Senior Vice President and Chief Nurse Executive, every Chief Nursing Officer, and David Reich, MD, President, Mount Sinai Hospital and Mount Sinai Queens. Dr. Reich shared that one of the highlights of his career has been working with an academic Department of Nursing committed to research that immediately translates into better care for patients. Linda Valentino, DNP, RN, Chief Nursing Officer, Mount Sinai Hospital, and Jill Goldstein, MA, MS, RN, Vice President Patient Services and Deputy Chief Nurse Officer, Mount Sinai Queens, were on site for much of the day to welcome nurses and thank them for their dedication to taking on challenging projects that advance practice.

Kicking off the formal agenda, keynote speaker Susan Reinhard, PhD, RN, FAAN, Senior Vice President and Director, AARP Public Policy Institute and Chief Strategist, Center to Champion Nursing in America and Family Caregiving Initiatives, presented “Health Care Transitions: Translating Research into Policy and Practice.” Dr. Reinhard’s extensive work focuses on advocating for the more than 50 million family caregivers in the United States. Her research contributed to the enactment of the Caregiver Advised Record and Enable (CARE) Act in 46 U.S. states and territories, ensuring the inclusion of a family caregiver’s name in the medical record of every hospital inpatient upon admission. Beyond data collection, Dr. Reinhard emphasized what it takes to be successful in research, including humanizing the data, engaging stakeholders, garnering media attention, and delving deeper into findings. Her research produced an evidence-based video series available online and for free to caregivers.

Shifting from a focus on caregiving to caring for caregivers, clinical psychologist Jonathan DePierro, PhD, Associate Professor of Psychiatry, Icahn Mount Sinai, and Associate Director, Center for Stress, Resilience, and Personal Growth, presented “Research-Driven Insights into Nursing Resilience, Mental Health, and Retention.” Dr. DePierro shared his team’s research on the individual and systematic contributors of burnout associated with working in a very high-stress, high-demand environment. He also outlined innovative programming offered through the Center and the Office of Well-Being and Resilience, which has the most comprehensive services to support clinician wellbeing in the nation.

The morning’s program also included presentations by the Evidenced-Based Practice Fellows at the Mount Sinai Phillips School of Nursing, which featured ABSN student Caroline Quinn’s findings on screening and intervening for postpartum depression and ABSN student Batsheva Weinberger’s findings on pediatric preoperative anxiety. This was followed by a robust poster session highlighting findings from nurses across the Health System, which can be found here. Select abstracts presented during the poster sessions will be published in a special issue of Practical Implementation of Nursing Science (PINS). Published by Mount Sinai’s Levy Library Press, PINS is an open access, peer-reviewed journal designed specifically for clinical nurses and nurse leaders to disseminate findings from the practice setting.

Dora Clayton-Jones, PhD, RN, CPNP-PC, FAAN

The afternoon programming began with a keynote address titled “Utilizing Community Assets to Support Self-Management in Health Care Transitions,” given by Dora Clayton-Jones, PhD, RN, CPNP-PC, FAAN, Associate Professor, Marquette University College of Nursing, and Immediate Past President, International Association of Sickle Cell Nurses and Professional Associates.

An accomplished clinician and nurse researcher, Dr. Clayton-Jones shared lessons learned from growing up on the West Side of Chicago, where she was influenced by a grandmother who involved her in community service activities to address food insecurity. “One thing that I learned was how to make it easy for people to ask for assistance,” said Dr. Clayton-Jones. “How easy are we making it for individuals to reach out for help when they need help?”

She encouraged participants to translate any lessons or approaches they could learn from her work in sickle cell disease—which effects millions worldwide—into their own practices and specialties. Following a general overview of sickle cell disease and the importance of a gradual and uninterrupted transition from pediatric to adult care, Dr. Clayton-Jones addressed her deep passion for community engagement, with a focus on leveraging community assets, translating community engagement activities into interventions, and the impact of community driven self-management interventions.

A panel discussion followed between Dr. Clayton-Jones and the Mount Sinai Comprehensive Sickle Cell Program leadership, including Director Jeffrey Glassberg, MD, MA, and nurse practitioners Charleen Jacobs, PhD, RN, ANP-BC, and Brittany McCrary, MS, AGPCNP-BC, RN-BC. This conversation touched upon Dr. Clayton-Jones’ career path and approaches to surmounting challenges, community involvement, lifelong learning, research, and funding.

Shifting the focus to innovations at Mount Sinai’s own Transitions of Care Center, Carl Jin, MSN, MPA, RN-BC, CCM, Director of Clinical Services, and Arzellra Walters, MA, CPNP, RN, Nurse Manager, presented “A Comprehensive Approach to Transitions of Care: The Expansion of the Transitions of Care Center’s Intervention.”

The Transitions of Care Center is a centralized discharge program staffed by Mount Sinai nurses trained in hospital discharge protocols to promote smooth transitions across levels of care. The ultimate goal is to prevent avoidable readmissions, with a focus on key diagnoses including acute myocardial infarction, chronic obstructive pulmonary disease, heart failure, pneumonia, coronary artery bypass grafting, and major joint replacement surgery. Transitioning between levels of care can be stressful, burdensome, and expensive for patients, caregivers, insurers, and hospitals. Mount Sinai’s Transitions of Care Center is testing the effects of a new model that eases the transition from hospital to home and reduces the risk of readmission.

The day concluded with a presentation about Mount Sinai’s exciting new national research training program for Doctor of Nursing Practice (DNP) students, Translational Research and Implementation Science for Nurses (TRAIN). Kimberly Souffront, PhD, RN, FNP-BC, FAAN, Associate Professor of Emergency Medicine at Icahn Mount Sinai and Associate Director of the CNRI, who is Principal Investigator of TRAIN along with Dr. Cohen, provided an overview of this first-of-its-kind program.

TRAIN supports DNP students from underrepresented minority communities and disadvantaged backgrounds to become experts in translating research into clinical practice. The program is funded by a five-year grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and its first annual cohort will begin this summer.

2024 Jacobi Medallion Award Ceremony

Seated, from left: Helen M. Fernandez, MD, MPH, MSH ’01; Marla C. Dubinsky, MD; Emma Guttman-Yassky, MD, PhD; Roxana Mehran, MD, MSH ’95; and Stephen Harvey, CPA, MBA. Standing, from left: Dennis Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai; Stuart A. Aaronson, MD; Peak Woo, MD; Mark Kostegan, FAHP; Kirk N. Campbell, MD; Sandra K. Masur, PhD, FASCB; Brendan G. Carr, MD, MA, MS, Chief Executive Officer of the Mount Sinai Health System; and Leo M. Keegan, MD, MSSM ’86, MSH ’94. Not pictured: Jeremy H. Boal, MD, MSH ’96

The Mount Sinai Alumni Association and Icahn School of Medicine at Mount Sinai presented accomplished physicians, researchers, educators, and administrators with the 2024 Jacobi Medallion, one of Mount Sinai’s highest awards. The annual ceremony was held Thursday, March 14, at the Plaza Hotel.

The recipients of the Jacobi Medallion have made exceptional contributions to the Mount Sinai Health System, Icahn Mount Sinai, the Mount Sinai Alumni Association, or the fields of medicine or biomedicine.

Watch the ceremony

View the digital program

Watch the In Memoriam video

Stuart A. Aaronson, MD

Founding Chair Emeritus, Department of Oncological Sciences

Jane B. and Jack R. Aron Professor of Neoplastic Diseases, Icahn School of Medicine at Mount Sinai

Associate Director for Basic and Translational Research, The Tisch Cancer Institute’s NCI-designated Cancer Center

Watch a video of Dr. Aaronson

Jeremy H. Boal, MD, MSH ’96

Executive Vice President and Chief Clinical Officer, Mount Sinai Health System, and President of Mount Sinai Beth Israel and Downtown until December 2023

Department of Population Health Science and Policy

Watch a video of Dr. Boal

Kirk N. Campbell, MD

Irene and Dr. Arthur M. Fishberg Professor of Medicine in the Division of Nephrology

Professor of Pharmacological Sciences

Founding Director of the Center for Kidney Disease Innovation

Icahn School of Medicine at Mount Sinai

Watch a video of Dr. Campbell

Marla C. Dubinsky, MD

Professor of Pediatrics and Medicine, Icahn School of Medicine at Mount Sinai

Chief of Pediatric Gastroenterology and Nutrition, Mount Sinai Kravis Children’s Hospital

Co-Director of the Susan and Leonard Feinstein IBD Clinical Center

Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai

Watch a video of Dr. Dubinsky

Helen M. Fernandez, MD, MPH, MSH ’01

Vice Chair of Education, Brookdale Department of Geriatrics and Palliative Medicine

Icahn School of Medicine at Mount Sinai

Watch a video of Dr. Fernandez

Emma Guttman-Yassky, MD, PhD

Waldman Professor of Dermatology and Immunology

Health System Chair of the Department of Dermatology

Director, Center for Excellence in Eczema and the Laboratory for Inflammatory Skin Diseases

Icahn School of Medicine at Mount Sinai

Watch a video of Dr. Guttman-Yassky

Stephen Harvey, CPA, MBA

Chief Financial Officer, Mount Sinai Health System

Watch a video of Mr. Harvey

Mark Kostegan, FAHP

Chief Development Officer and Senior Vice President for Development at Mount Sinai

Watch a video of Mr. Kostegan

Roxana Mehran, MD, MSH ’95

Professor of Medicine

Director of Interventional Cardiovascular Research and Clinical Trials, Zena and Michael A. Wiener Cardiovascular Institute

Icahn School of Medicine at Mount Sinai

Watch a video of Dr. Mehran

Peak Woo, MD

Clinical Professor, Department of Otolaryngology and Head and Neck Surgery

Icahn School of Medicine at Mount Sinai

Watch a video of Dr. Woo

The Center for Advanced Medical Simulation at Mount Sinai West Hosts Annual Tristate Regional Simulation Symposium May 17

The Center for Advanced Medical Simulation (CAMS) at Mount Sinai West is hosting its pioneering annual Tristate Regional Simulation Symposium. The symposium is scheduled for Friday, May 17, from 11 am to 2 pm, using a live online format.

The theme for this eighth annual symposium is “Embracing Change: How Artificial Intelligence (AI) Can Influence Health Care Simulation.” The symposium will include plenary talks, data-driven presentations, and panel discussions.

“Together, we will explore AI possibilities to enhance patient safety, team performance, and outcomes in simulation-based education and powerfully affirm everything that is most striking about simulation that we do at our institutions and worldwide,” said Priscilla V. Loanzon, EdD, RN, CHSE, Director of Simulation Education, Center for Advanced Medical Simulation, and Assistant Professor of Medicine (Pulmonary, Critical Care, and Sleep Medicine) at the Icahn School of Medicine at Mount Sinai.

Since the pandemic, the format for the symposium has changed from a full-day onsite and in-person conference to a three-hour live online. The target audience has expanded over the years from regional to national and international. Attendees can earn credits for continuing medical education and continuing education units.

CAMS is one of the Mount Sinai Health System’s outstanding simulation centers, all dedicated to improving patient safety, communication, and medical education. It provides health care training opportunities to professionals in the safe learning environment of a lab setting, offering courses that include case-based simulation, in-situ simulation, and procedural training such as point of care ultrasonography, central line training, blood culture competency, medical code response, managing mechanically ventilated patients, and advanced airway management. The Center includes three simulation laboratories, a virtual-reality training arcade, and two conference rooms. All areas of CAMS are equipped with audiovisual and video-recording equipment to facilitate education, training, debriefing, and research and quality improvement projects.

The Center, accredited by the Society for Simulation in Healthcare (SSH), is working with the Continuing Medical Education Department, Mount Sinai’s Office of Corporate Compliance and Office of Development.

To learn more about the symposium, contact Dr. Loanzon at priscilla.loanzon@mountsinai.org or call 212-523-8698.

The Society for Simulation in Healthcare declared September 11-15, 2017, as an inaugural simulation week with a focus on celebrating the professionals who work in health care simulation to improve the safety, effectiveness, and efficiency of health care.

“CAMS invited the simulation centers in the tristate area to a joint celebration through a symposium,” said Dr. Loanzon. “This inaugural celebration was intended to powerfully affirm the tristate region’s successes, opportunities, and myriad possibilities to be the best in what we do so well individually and collectively.”

Pin It on Pinterest